Evaluation of lipoproteins/apolipoproteins as therapeutic agents for the treatment of vascular and nonvascular disease

American Journal of Cardiology

Volumn 81, Issue 8 A, 1998, Pages 36F-39F

  Sirtori, Cesare R ^a   Dujovne, Carlos A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Kansas Foundation for Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CONFERENCE PAPER; DEGENERATIVE DISEASE; GOUT; INFLAMMATION; LIPID STORAGE; LIPOPROTEIN METABOLISM; OBESITY; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032560219     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00259-8     Document Type: Conference Paper

References (41)

1. Akerlöf E, Fredricsson B, Gustafson O, Lunell N-O, Nylund L, Rosenborg L, Pousette A. Serum factors stimulate the motility of human spermatozoa. Int J Androl 1987;10:124-130.
2. Akerlöf E, Jörnvall H, Slotte H, Pousette A. Identification of apolipoprotein AI and immunoglobulin as components of a serum complex that mediates activation of human sperm motility. Biochemistry 1991;30:8986-8990.
3. Pousette A, Leijonhufvud PK, Akerlöf E. Purification, structure and partial characterization of the major sperm activating protein complex in human serum. Scand J Clin Lab Invest 1993;213:39-44.
4. Terkeltaub RA, Dyer CA, Martin J, Curtiss LK. Apolipoprotein (Apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. J Clin Invest 1991;87:20-26.
5. Chisari FV, Curtiss LK, Jensen FC. Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by Epstein-Barr virus. J Clin Invest 1981;68:329-336.
6. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986;136:3716-3723.
7. Skene JHP, Shooter EM. Denervated sheath cells secrete a new protein after nerve injury. Proc Natl Acad Sci USA 1983;80:4169-4173.
8. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
9. Strittmatter WJ, Weisgraber KH, Huang D, Dong L-M, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to βA4 peptide: isoform-specific effects and implications for late-onset Alzheimers disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
10. Ignatius MJ, Shooter EM, Pitas RE, Mahley RW. Lipoprotein uptake by neuronal growth cones in vitro. Science 1987;236:959-962.
11. Goodrum JF. Cholesterol from degenerating nerve myelin becomes associated with lipoproteins containing apolipoprotein E. J Neurochem 1991;56:2082-2086.
12. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 1994;264:850-852.
13. Whitson JS, Mims MP, Strittmatter WJ, Yamaki T, Morrissett JS, Appel SH. Attenuation of the neurotoxic effect of Ab amyloid peptide by apolipoprotein E. Biochem Biophys Res Comm 1994;199:163-170.
14. Nathan BP, Chang K-C, Bellosta S, Brisch E, Ge N, Mahley RW, Pitas RE. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem 1995;270:19791-19799.
15. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46:1580-1584.
16. Hayagashi H, Nutting D, Fujimoto K, Cardelli JA, Black D, Tso P. Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat. J Lipid Res 1990;31:1613-1625.
17. Fujimoto K, Cardelli JA, Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after a lipid meal acts as a physiological signal for satiation. Am J Physiol 1992;262:41002-41006.
18. Fujimoto K, Machidori H, Iwakiri R, Yamamoto K, Fujisaki J, Sakata T, Tso P. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity of rats. Brain Res 1993;608:233-237.
19. Fujimoto K, Fukagawa K, Sakata T, Tso P. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 1993;91:1830-1833.
20. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993;90:12040-12044.
21. Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995;126:548-558.
22. Lerch PG, Förtsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 1996;71:155-164.
23. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJH. Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996;184:1601-1608.
24. Hussain MM, Mahley RW, Boyles JK, Fainaru M, Brecht WJ, Lindquist PA. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. J Biol Chem 1989;264:9571-9582.
25. Nykjaer A, Bengtsson-Olivecrona G, Lookene A, Moestrup SK, Petersen CM, Weber W, Beisiegel V, Gliemann J. The a2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase. J Biol Chem 1993;268:15048-15055.
26. Mahley RW, Weisgraber KH, Hussain MM, Greenman B, Fisher T, Vogel T, Gorecki M. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest 1989;83:2125-2130.
27. Yamada N, Inoue I, Kawamura M, Harada K, Watanabe Y, Shimano H, Gotoda T, Shimada M, Kohzaki K, Tsukada T, et al. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1992;89:706-711.
28. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic streaks in cholesterol-fed rabbits. Lab Invest 1989;60:455-461.
29. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerosis lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;1234-1241.
30. Aoyama T, Yui Y, Morishita H, Kawai C. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 1990;81:1784-1791.
31. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39:1-8.
32. Duverger N, Kruth H, Emmanuel F, Caillaud J-M, Viglietta C, Castro G, Tailleux Fievet C, Fruchart J-C, Houdebine LM, Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenie rabbits. Circulation 1996;94:713-717.
33. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakatamata H, Sakamoto Yu-I, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apo lipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995;15:1882-1888.
34. Milano. Accelerated binding and dissociation from lipids of a human apo lipoprotein variant. J Biol Chem 1985;260:16321-16325.
35. Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993;91:1445-1452.
36. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994;90: 1935-1941.
37. Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995;76:405-411.
38. Carlson LA. Effect of a single infusion of recombinant human pro apolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr Med Cardiovasc Dis 1995;5:85-91.
39. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler J-J, Lerch P, Miller NE. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 1996;16:1203-1214.
40. Duverger N, Tremp G, Caillaud J-M, Emmanuel F, Castro G, Fruchart J-C, Steinmetz A, Denèfle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996;273:966-968.
41. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993;88:2541-2547.